GLP-TZ 5MG
The dual-pathway sibling of GLP-RT — one 5mg fill.
What GLP-TZ is, in plain English.
GLP-TZ is a synthetic peptide of 39 amino acids built on the sequence of GIP, one of the two incretin hormones the gut releases after a meal, and engineered to act at two receptors, GIP and GLP-1: the dual pathway beside GLP-RT's three. It binds the GIP receptor more strongly than the GLP-1 receptor. Like its sibling it carries a C20 fatty-acid side chain that binds albumin in circulation and extends its half-life to about five days, where the natural hormones last only minutes; that long action is the defining feature of this generation of metabolic peptides. It is the most extensively published compound of the class, commonly researched in metabolic models covering glucose handling, energy balance and body composition, and in work on how the two incretin signals combine. It is also the best documented in people of anything in this range: the molecule has been through large human trials and has been a licensed medicine in the United States and the European Union since 2022. What is supplied here is not that medicine and is not a licensed product. Supplied as 5mg of freeze-dried powder per vial, for reconstitution with bacteriostatic water; store at 2–8°C.
